As stated previously, I usually don’t write about experimental research unless there is a good reason to do so. Preliminary findings have a way of changing. That’s why they are preliminary.
However, glioblastoma is a common form of brain tumor, and the five-year survival rate is a pathetic 5%. Further we have a class of experimental drugs, one of the most promising of which is designated KL-50, that may be in clinical trials in the relatively near future and that preliminary testing has shown to be quite effective against this horrible disease.
This new class of drugs is a direct attack on the disease. They cause fatal damage to the DNA of cancer cells without harming non-cancerous cells in the body.
Cancer cells are simply normal cells that have incurred mutations causing uncontrolled growth. There are a variety of factors that can cause these mutations, including chemicals, radiation and types…
View original post 433 more words


You must be logged in to post a comment.